Pharmacokinetics (PK) of lonafarnib (L), a farnesyl protein transferase inhibitor.

被引：0
|
作者：
Zhu, Y [1 ]
Statkevich, P [1 ]
Cutler, DL [1 ]
Calzetta, A [1 ]
Curtis, D [1 ]
Batra, VK [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P59 / P59
页数：1
相关论文
共 50 条
  • [11] Clinical pharmacokinetics of Irinotecan given in combination with the farnesyl transferase inhibitor ZARNESTRA™.
    Kehrer, DF
    Sparreboom, A
    De Jonge, MJ
    De Heus, G
    Palmer, P
    Bol, C
    Verweij, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3744S - 3744S
  • [12] Evaluation of farnesyl: protein transferase and geranylgeranyl:: Protein transferase inhibitor combinations in preclinical models
    Lobell, RB
    Omer, CA
    Abrams, MT
    Bhimnathwala, HG
    Brucker, MJ
    Buser, CA
    Davide, JP
    deSolms, SJ
    Dinsmore, CJ
    Ellis-Hutchings, MS
    Kral, AM
    Liu, DM
    Lumma, WC
    Machotka, SV
    Rands, E
    Williams, TM
    Graham, SL
    Hartman, GD
    Oliff, AI
    Heimbrook, DC
    Kohl, NE
    CANCER RESEARCH, 2001, 61 (24) : 8758 - 8768
  • [13] Pharmacokinetics (PK) of COL-3, a matrix metalloproteinase (MMP) inhibitor.
    Rudek, MA
    Dyer, V
    Dahut, W
    Pluda, JM
    Reed, E
    Figg, WD
    CLINICAL CANCER RESEARCH, 2000, 6 : 4524S - 4524S
  • [14] The farnesyl transferase inhibitor lonafarnib combined with the RAF inhibitor sorafenib potently inhibits growth and induces apoptosis of metastatic melanoma cells
    Niessner, H.
    Sinnberg, T.
    Schittek, B.
    Lasithiotakis, K.
    Maczey, E.
    Garbe, C.
    Meier, F.
    EXPERIMENTAL DERMATOLOGY, 2008, 17 (03) : 277 - 277
  • [15] The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells
    Niessner, Heike
    Beck, Daniela
    Sinnberg, Tobias
    Lasithiotakis, Konstantinos
    Maczey, Evelyn
    Gogel, Jeannette
    Venturelli, Sascha
    Berger, Alexander
    Mauthe, Mario
    Toulany, Mahmoud
    Flaherty, Keith
    Schaller, Martin
    Schadendorf, Dirk
    Proikas-Cezanne, Tassula
    Schittek, Birgit
    Garbe, Claus
    Kulms, Dagmar
    Meier, Friedegund
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (02) : 468 - 479
  • [16] The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase
    Marcus, AI
    Zhou, J
    O'Brate, A
    Hamel, E
    Wong, J
    Nivens, N
    El-Naggar, A
    Yao, TP
    Khuri, FR
    Giannakakou, P
    CANCER RESEARCH, 2005, 65 (09) : 3883 - 3893
  • [17] The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
    Niessner, H.
    Sinnberg, T.
    Beck, D.
    Kulms, D.
    Lasithiotakis, K.
    Flaherty, K.
    Schittek, B.
    Schaller, M.
    Schadendorf, D.
    Garbe, C.
    Meier, F.
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2010, 89 : 51 - 52
  • [18] Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study
    Christophe Ravoet
    Philippe Mineur
    Valérie Robin
    Louisette Debusscher
    André Bosly
    Marc André
    Hakim El Housni
    Anne Soree
    Dominique Bron
    Philippe Martiat
    Annals of Hematology, 2008, 87 : 881 - 885
  • [19] Synergistic suppression of metastatic phenotype in vitro and metastasis in vivo by a bisphosphonate plus a farnesyl transferase inhibitor.
    Andela, V
    Schwarz, E
    O'Keefe, R
    Rosenblatt, J
    Puzas, E
    Rosier, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S192 - S192
  • [20] Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
    Wang, Jialiang
    Lian, Yifan
    Gu, Yurong
    Wang, Hongbo
    Gu, Lin
    Huang, Yanlin
    Zhou, Liang
    Huang, Yuehua
    ONCOTARGET, 2017, 8 (62) : 105047 - 105060
12345